Secukinumab

Summary

Secukinumab (CHEMBL1743068) is an approved antibody (ATC L04AC10); indicated across 32 conditions including ankylosing spondylitis and psoriasis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AC10
• Indications: 32 conditions
• Clinical trials: 205

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743068
Name	Secukinumab
Type	Antibody
Max phase	4
ATC	L04AC10

Also known as: AIN-457, AIN457, AIN457A, Cosentyx, Secukinumab, SECUKINUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
ankylosing spondylitis	4	MONDO:0005306	EFO:0003898
psoriasis	4	MONDO:0005083	EFO:0000676
psoriatic arthritis	4	MONDO:0011849	EFO:0003778
immune system disorder	4	MONDO:0005046	EFO:0000540
spondyloarthropathy	4	MONDO:0005095	EFO:0000706

25 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
rheumatoid arthritis	3	MONDO:0008383	EFO:0000685
Behcet disease	3	MONDO:0007191	EFO:0003780
uveitis	3	MONDO:0020283	EFO:1001231
hidradenitis suppurativa	3	MONDO:0006559	EFO:1000710
disease of the tendon	3	MONDO:0100010	EFO:1001434
polymyalgia rheumatica	3	MONDO:0019735	EFO:0008518
temporal arteritis	3	MONDO:0008538	EFO:1001209
lupus nephritis	3	MONDO:0005556	EFO:0005761
osteoarthritis	3	MONDO:0005178	MONDO:0005178
alopecia areata	2	MONDO:0005340	EFO:0004192
Crohn disease	2	MONDO:0005011	EFO:0000384
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
pyoderma	2	MONDO:0002922	HP:0000999
atopic eczema	2	MONDO:0004980	EFO:0000274
dry eye syndrome	2	MONDO:0006733	EFO:1000906
necrobiosis lipoidica	2	MONDO:0006583	EFO:1000738
discoid lupus erythematosus	2	MONDO:0019558	MONDO:0019558
lichen planus	2	MONDO:0006572	EFO:0009856
asthma	2	MONDO:0004979	MONDO:0004979
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
inflammatory bowel disease	2	MONDO:0005265	EFO:0003767
rosacea	1	MONDO:0006604	EFO:1000760
pityriasis rubra pilaris	1	MONDO:0100017	MONDO:0100017

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 205.

Phase distribution

Phase	Trials
PHASE3	89
PHASE2	38
PHASE4	31
Not specified	28
PHASE1	13
PHASE1/PHASE2	5
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04239859	PHASE4	NOT_YET_RECRUITING	Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
NCT05622708	PHASE4	ACTIVE_NOT_RECRUITING	A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
NCT06833112	PHASE4	NOT_YET_RECRUITING	Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07489573	PHASE4	NOT_YET_RECRUITING	Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT02144857	PHASE4	UNKNOWN	Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
NCT02547714	PHASE4	COMPLETED	Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
NCT02592018	PHASE4	COMPLETED	Immunologic Response to Secukinumab in Plaque Psoriasis
NCT02690701	PHASE4	COMPLETED	Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
NCT02752776	PHASE4	COMPLETED	A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
NCT02798211	PHASE4	COMPLETED	Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
NCT03020199	PHASE4	COMPLETED	Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
NCT03055494	PHASE4	COMPLETED	Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
NCT03307447	PHASE4	UNKNOWN	Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).
NCT03350815	PHASE4	COMPLETED	Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
NCT03440736	PHASE4	COMPLETED	Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
NCT03445845	PHASE4	COMPLETED	Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
NCT03623867	PHASE4	COMPLETED	PsA Secukinumab XCT Structural Progression Study
NCT03639740	PHASE4	UNKNOWN	Treat-to-target With Secukinumab in Axial Spondyloarthritis
NCT04340076	PHASE4	COMPLETED	Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
NCT04469829	PHASE4	UNKNOWN	Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
NCT04488185	PHASE4	WITHDRAWN	An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound
NCT04535999	PHASE4	COMPLETED	Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
NCT04571567	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
NCT04717466	PHASE4	COMPLETED	Brain Changes in Psoriasis After Secukinumab Treatment
NCT04887597	PHASE4	UNKNOWN	EBIO - Enthesitis Biopsy Study
NCT04996485	PHASE4	UNKNOWN	Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
NCT05080218	PHASE4	COMPLETED	COVID-19 VaccinE Response in Rheumatology Patients
NCT05527444	PHASE4	UNKNOWN	The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
NCT05676333	PHASE4	COMPLETED	Secukinumab in Active Non-segmental Vitiligo
NCT05891964	PHASE4	COMPLETED	Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
NCT04179175	PHASE3	ACTIVE_NOT_RECRUITING	Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
NCT06331312	PHASE3	ACTIVE_NOT_RECRUITING	Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06630559	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
NCT06945107	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
NCT00995709	PHASE3	COMPLETED	Phase III Study in Refractory Behcet’s Disease
NCT01032915	PHASE3	TERMINATED	Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01090310	PHASE3	TERMINATED	Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01093846	PHASE3	TERMINATED	38 Week Extension Study to CAIN457C2303
NCT01095250	PHASE3	TERMINATED	Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01103024	PHASE3	WITHDRAWN	Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01327664	PHASE3	WITHDRAWN	Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01350804	PHASE3	COMPLETED	Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
NCT01358175	PHASE3	COMPLETED	16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01358578	PHASE3	COMPLETED	Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
NCT01365455	PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year
NCT01377012	PHASE3	COMPLETED	Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
NCT01392326	PHASE3	COMPLETED	Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
NCT01406938	PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
NCT01412944	PHASE3	COMPLETED	Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
NCT01544595	PHASE3	COMPLETED	Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
NCT01555125	PHASE3	COMPLETED	First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
NCT01636687	PHASE3	COMPLETED	Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
NCT01640951	PHASE3	COMPLETED	4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01649375	PHASE3	COMPLETED	16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
NCT01752634	PHASE3	COMPLETED	Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
NCT01770379	PHASE3	TERMINATED	Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.
NCT01806597	PHASE3	COMPLETED	Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
NCT01807520	PHASE3	COMPLETED	Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
NCT01863732	PHASE3	COMPLETED	Extension in AS: Sustainability of Benefits, Safety and Tolerability
NCT01892436	PHASE3	COMPLETED	Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
NCT01952015	PHASE3	COMPLETED	Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
NCT01961609	PHASE3	COMPLETED	Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
NCT01989468	PHASE3	COMPLETED	24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
NCT02008890	PHASE3	COMPLETED	Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
NCT02008916	PHASE3	COMPLETED	16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
NCT02074982	PHASE3	COMPLETED	Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
NCT02159053	PHASE3	COMPLETED	16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
NCT02267135	PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
NCT02294227	PHASE3	COMPLETED	16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
NCT02362789	PHASE3	COMPLETED	Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
NCT02394561	PHASE3	COMPLETED	A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
NCT02404350	PHASE3	COMPLETED	Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
NCT02409667	PHASE3	COMPLETED	Plaque Psoriasis Efficacy and Safety With Secukinumab
NCT02474069	PHASE3	COMPLETED	Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
NCT02474082	PHASE3	COMPLETED	Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.
NCT02559622	PHASE3	COMPLETED	Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
NCT02595970	PHASE3	COMPLETED	Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02662985	PHASE3	COMPLETED	Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
NCT02696031	PHASE3	COMPLETED	Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
NCT02721966	PHASE3	COMPLETED	Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
NCT02745080	PHASE3	COMPLETED	Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
NCT02748863	PHASE3	COMPLETED	Study of Secukinumab With 2 mL Pre-filled Syringes
NCT02771210	PHASE3	COMPLETED	Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
NCT02778711	PHASE3	UNKNOWN	Anti-IL-17 a New Treatment for Contact Dermatititis
NCT02826603	PHASE3	COMPLETED	Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
NCT02896127	PHASE3	COMPLETED	Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
NCT03031782	PHASE3	COMPLETED	Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
NCT03090100	PHASE3	COMPLETED	A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
NCT03136861	PHASE3	COMPLETED	SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
NCT03259074	PHASE3	COMPLETED	Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT03358134	PHASE3	COMPLETED	Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
NCT03478787	PHASE3	COMPLETED	Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
NCT03504852	PHASE3	COMPLETED	Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
NCT03535194	PHASE3	COMPLETED	A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
NCT03536884	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT03589885	PHASE3	COMPLETED	Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
NCT03713619	PHASE3	COMPLETED	This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
NCT03713632	PHASE3	COMPLETED	Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03769168	PHASE3	COMPLETED	An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).